MicrobiotiX Secures KRW 20 Billion Series B to Launch Korea's First Bacteriophage Clinical Trial
核心洞察
MicrobiotiX (搜索) completed a KRW 20 billion Series B funding round, bringing total cumulative investment to KRW 29 billion across all rounds.
The company received a KRW 2.5 billion clinical grant from Korea's Ministry of Health and Welfare to conduct the nation's first human bacteriophage therapy (搜索) trial.
MicrobiotiX (搜索) develops bacteriophage-based therapeutics targeting multidrug-resistant bacterial infections (搜索) using a comprehensive platform including phage libraries and cGMP manufacturing capabilities.
MicrobiotiX (搜索), a South Korean biotechnology company developing bacteriophage-based therapeutics, has completed a KRW 20 billion Series B funding round and secured government support to launch Korea's first human clinical trial of phage therapy (搜索). The milestone positions the company to address the growing global threat of multidrug-resistant bacterial infections (搜索).
Funding Milestone Reached
The company announced on August 29, 2025, that it had finalized its extended Series B investment round, raising an additional KRW 5 billion from new investors including Paratus Investment (搜索), Pureun Investment (搜索), and OTIUM CAPITAL (搜索). This follows an initial KRW 15 billion Series B investment secured in October 2024, bringing MicrobiotiX (搜索)'s cumulative investment across all funding rounds to KRW 29 billion.
Government Support for Clinical Development
MicrobiotiX (搜索) was selected for the Korean Ministry of Health and Welfare (搜索)'s "Infectious Disease Prevention and Treatment Technology Development Project," securing a KRW 2.5 billion clinical award. This government funding specifically targets clinical-stage assets addressing unmet medical needs and will enable MicrobiotiX to conduct the first-ever human clinical trial of phage therapy (搜索) in Korea.
Comprehensive Phage Therapy Platform
The company has developed a comprehensive platform for bacteriophage therapy (搜索) development targeting diseases caused by multidrug-resistant bacteria (搜索). MicrobiotiX (搜索)'s platform includes a phage library panel specifically designed to target multidrug-resistant bacteria, an in silico computational module, and a cGMP-grade phage manufacturing facility.
Strategic Vision for Global Leadership
Dongeun Yong, CEO of MicrobiotiX (搜索), outlined the company's ambitious goals following the funding completion. "With this investment and the government project selection, MicrobiotiX seeks to establish itself and Korea as a global leader in the phage therapy (搜索) field," Yong stated. "Through conducting the first clinical trial of its kind in Korea, we are responding to the global health crisis presented by antibiotic-resistant bacterial infections (搜索)."
The CEO emphasized the broader implications for Korea's biotechnology sector, noting that the company aims to "further enhance the competitiveness and global status of the Korean bio-industry" while continuing to "grow as a Korean biotech company that leads the development of innovative anti-infective drugs."
Accelerating Commercialization
The combined private investment and government funding will accelerate MicrobiotiX (搜索)'s research and development efforts toward commercialization of phage therapies and expansion of its therapeutic pipeline. The company's focus on multidrug-resistant bacterial infections (搜索) addresses a critical global health challenge where traditional antibiotic treatments have become increasingly ineffective.